Olink_full_OMICS.xlsx

Placental proteins were extracted and analyzed using five Olink Target 96 panels (Olink Proteomics): Cardiovascular II, Cardiovascular III, Development, Inflammation, and Oncology III. We measured 452 unique proteins in each placenta. Samples were processed in batches with pooled quality-control samples, which were included in each batch. All assay-validation data (detection limits, intra-, and inter-assay precision data) are available on the manufacturer’s website (www.olink.com).Placental biopsies were obtained from the Steve N. Caritis Magee Obstetric Maternal and Infant (MOMI) Database and Biobank at Magee-Womens Research Institute and the Health Record Research Request Service at the University of Pittsburgh. Samples were biobanked from 2010-2019 and had placental histopathological analyses conducted by a condition-blinded pathologist. We included placentas obtained from people ages 15-45 delivering singleton live births between 23-42 weeks of gestation. Placentas were obtained from women with the following conditions: control (delivery after 37 weeks of gestation with no complications), control preterm delivery (control PTD; induced delivery before 37 weeks of gestation with no further complications), spontaneous preterm delivery (PTD), severe preeclampsia (PE), and severe fetal growth restriction (FGR, bottom 3rd percentile for weight by gestational age at delivery) with and without hypertension.